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Development of a personalized decision aid for
breast cancer risk reduction and management
Elissa M Ozanne1,2*, Rebecca Howe3, Zehra Omer4 and Laura J Esserman3
Abstract
Background: Breast cancer risk reduction has the potential to decrease the incidence of the disease, yet remains
underused. We report on the development a web-based tool that provides automated risk assessment and personalized
decision support designed for collaborative use between patients and clinicians.
Methods: Under Institutional Review Board approval, we evaluated the decision tool through a patient focus group,
usability testing, and provider interviews (including breast specialists, primary care physicians, genetic counselors). This
included demonstrations and data collection at two scientific conferences (2009 International Shared Decision Making
Conference, 2009 San Antonio Breast Cancer Symposium).
Results: Overall, the evaluations were favorable. The patient focus group evaluations and usability testing (N = 34)
provided qualitative feedback about format and design; 88% of these participants found the tool useful and 94% found
it easy to use. 91% of the providers (N = 23) indicated that they would use the tool in their clinical setting.
Conclusion: BreastHealthDecisions.org represents a new approach to breast cancer prevention care and a framework for
high quality preventive healthcare. The ability to integrate risk assessment and decision support in real time will allow for
informed, value-driven, and patient-centered breast cancer prevention decisions. The tool is being further evaluated in
the clinical setting.
Keywords: Breast cancer, Decision aid, Risk assessment, Risk reduction, Decision making, Primary care
Background
Involving women in decisions related to their own health is
integral to the adoption of preventative health measures.
This is particularly true in efforts intended to reduce breast
cancer incidence. For example, although more than 2.4 mil-
lion women in the United States are projected to benefit
from breast cancer risk-reducing medications such as tam-
oxifen or raloxifene [1,2], fewer than 1% of eligible patients
elect to take them [3,4]. This low utilization rate is largely
due to clinician difficulties in assessing patients’ risk, pa-
tients’misperceptions of their own risk of developing breast
cancer, and the lack of familiarity on the part of both pa-
tients and clinicians with the risks and benefits of these
medications [5]. Given the prevalence of breast cancer and
the efficacy of available preventive interventions [6],
addressing the challenge of risk assessment and risk reduc-
tion should be a fundamental part of women’s clinical care.
Making well-informed decisions about breast cancer risk
reduction requires women to weigh the benefits and risks
of the options and determine how they value the possible
outcomes of each. In addition, women’s risk of breast can-
cer and preferences for interventions around breast cancer
screening and risk reduction vary widely and must be in-
cluded in their decision making. In this setting, there is a
need for: 1) personalized risk assessment, 2) unbiased,
comprehensive education about the options for risk reduc-
tion, and 3) an opportunity for meaningful consideration
of the risks and benefits involved on the part of the
patient.
Decision aids are tools designed to support informed
medical decision making and can facilitate efficient com-
munication between patients and clinicians about these
risks and benefits. These tools offer enhanced knowledge
about interventions, allowing women the opportunity to
weigh the risks and benefits of their choices. They have
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been shown to help patients increase their knowledge of
their options, to reduce their decisional conflict, and to
make decisions that align with their goals and values
[7,8]. Clinical decision aids have been developed for a
broad range of health issues; however, few decision aids
have been developed for breast cancer risk reduction.
Those that have been developed for clinical use are in
the form of generic DVDs, CD-ROMs and written edu-
cational materials [9-11] designed for a single risk-
reduction option or intended for small subgroups of
women, such as women considering genetic testing or
women with a known genetic mutation [3,12-16].
While these tools have been shown to be both feasible
and beneficial, they have a number of limitations. Most
are not tailored to patients’ individual breast cancer risk or
health characteristics. Also, they are not designed for use
within the primary care setting, where risk reduction ef-
forts are likely to have the strongest impact [7]. Further-
more, informed decision-making in the clinical setting can
be impeded by significant demands on physicians’ time,
incomplete and often conflicting data, and rapidly chan-
ging scientific evidence and consensus recommendations.
These factors often hinder informed decision-making in
the clinical setting, underscoring the value of decision sup-
port tools in this environment [17-19].
To address these decision-making challenges to breast
cancer risk reduction, we developed a comprehensive
framework to guide and inform consultations [20]. Based
on this framework, we developed a decision aid prototype,
intended to be used with patients being seen in a high-risk
clinic. It encourages informed decision making and aims
to align patient decisions with patient values and current
clinical knowledge. The tool was designed for collaborative
use between patients and clinicians, including primary
care physicians, cancer risk clinicians, and genetic coun-
selors, to provide both personalized risk assessment and
decision support pertaining to breast cancer risk reduc-
tion. The design was intended to be flexible so that the
tool could be used at any point in a clinical visit, including
before the visit as an educational primer.
The design of the decision aid prototype and assessment
of its clinical feasibility and effectiveness has been ex-
plained in depth previously [21]. It was developed and im-
plemented in the breast cancer prevention program at
UCSF, and piloted in a feasibility trial comparing consulta-
tions performed using it to standard consultations. It was
found to be clinically feasible and acceptable to both pa-
tients and providers in this setting. Although not powered
to detect an impact in efficacy, this initial evaluation ap-
peared to show beneficial effects in terms of patient know-
ledge and satisfaction.
To extend the generalizability and broaden the applic-
ability of the decision aid, we transitioned the prototype
into a web-based tool called BreastHealthDecisions.org
designed for multiple clinical settings, including primary
care clinics. In this paper, we describe the process used
to develop BreastHealthDecisions.org, the results of the
usability testing, and how stakeholder input was incor-
porated into the generalizable web-based tool.
Methods
BreastHealthDecisions.org was developed through an it-
erative research process that allowed for continuous im-
provement of the decision support tool. Research involved
assembling a team of expert advisors, developing the deci-
sion aid prototype, and evaluative work with key
stakeholders.
Theoretical framework
Our earlier framework and decision aid were guided by
the decision analytic framework developed by Howard
and colleagues [22,23]. The theoretical basis of decision
analysis consists of the following elements: 1) appropriate
framing, 2) creative alternatives, 3) quality information, 4)
consistent preferences, 5) clear logic, and 6) commitment
to action on the part of the decision maker. According to
the Howard Framework, attention to these six elements is
required for making quality decisions and were incorpo-
rated into our decision aid.
Development process
The content, format, and style of the decision aid were
developed using current literature on risk communica-
tion [24-28] as well as the advice of clinicians, health
policy analysts, decision analysts, information architec-
ture experts, and an advisory board. A scientific advis-
ory board of experts in breast cancer risk, and risk
reduction and management, was assembled to guide the
decision tool development process. The advisory board
consisted of leading experts in the field of breast cancer
prevention, including surgeons, oncologists, genetic coun-
selors, decision scientists, statisticians, primary care physi-
cians, epidemiologists, behavioral scientists, and patient
advocates. The advisory board met as a group to review
the first version of the decision aid and was consulted on a
regular basis regarding changes and improvements in the
decision aid.
The web tool, developed by Drs. Ozanne and Esserman
and colleagues at UCSF, generates tailored patient-specific
risk assessments using established risk models (including
Gail, BRCApro, Claus, BCSC density) based on patient data
[29-32]. Consultants from MAYA Viz, a company focused
on web design, provided format and style guidance and
aided the development of the tool’s information architec-
ture [33]. The International Patient Decision Aid Standards
(IPDAS) were also used to guide the development of the
decision aid where appropriate [34]. The IPDAS were de-
signed primarily for patient facing decision aids, while our
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tool is intended for use by a patient and clinician dyad.
Therefore we consulted the relevant criteria for our tool.
We have obtained the domain name www.BreastHealth-
Decisions.org to support open access for the decision aid.
The web-based version is designed for use by both pa-
tients and their providers, specifically breast specialists,
gynecologists, and primary care physicians. The tool uses
patent risk factors including family history of cancer and
patient biomarkers–such as atypia, breast density, and
genetic mutations–to generate estimates of risk and inter-
vention benefits.
The web-based tool was designed with the following
core characteristics:
 individual tailoring to patients’ breast cancer risk
and overall health using validated risk assessment
models,
 applicability to the primary care setting, by
providing content relevant to the general population
of women,
 addresses the risk of side effects from risk reduction
measures, one of the main barriers to use,
 designed for use at the time of the consultation,
facilitating communication between patients and
clinicians, and
 web-based platform, providing an easily accessible
platform for both patients and clinicians that can be
updated rapidly and disseminated broadly.
Usability testing
To evaluate the content and usability of BreastHealthDeci-
sions.org, qualitative data was collected through usability
testing with patients and health care providers. Discussions
with the primary users of the decision aid and relevant ex-
perts were conducted to provide us with information about
how to optimize the decision aid for future use in clinical
settings. We aimed to elicit feedback on the content, struc-
ture, ease of use, and design of the decision aid.
Participants
We targeted three groups of participants: patients, pro-
viders, and decision scientists and experts in shared
decision-making. The participants provided verbal con-
sent for the focus group and semi-structured interviews,
according to the research protocol that was reviewed
and approved by the institutional review boards at the
University of California, San Francisco and Massachusetts
General Hospital.
The patient focus group consisted of breast cancer sur-
vivors who were recruited from a list of volunteers at a
large cancer center. We chose breast cancer survivors to
avoid raising patient anxiety in women who had not previ-
ously been diagnosed with breast cancer. We also chose
them because they are knowledgeable about the issues
surrounding breast cancer and could provide their opinion
about the decision aid, but were not currently facing the
specific decisions described in the decision aid. The health
care provider participants were recruited at the 2009 San
Antonio Breast Cancer Symposium (SABCS), held in San
Antonio, TX. These participants, targeted as potential users
of the decision aid, were asked to complete pilot testing at
SABCS. Targeted evaluators included genetic counselors,
primary care physicians, surgeons, oncologists, and nurse
practitioners.
The final group of participants consisted of experts in
the field of decision sciences and shared decision-making.
These participants were recruited from the 2009 Inter-
national Shared Decision Making Conference (ISDM),
held in Boston, MA.
Data collection
A case study for a high-risk woman was presented to the
patient focus group participants and the group walked
through the decision aid as it would be used in a consult-
ation. After the presentation, a group discussion was initi-
ated by an experienced facilitator using a semi-structured
guide designed by the research team. The discussion lasted
for approximately two hours and was transcribed. The
participants commented on the usefulness of each section
of the decision aid. Participants also gave advice about the
relevance of the content, the ease of use of the design, and
general comments about the structure of the tool.
The health care provider participants viewed the web-
based decision aid and completed one-on-one interviews
with the principal investigator of the study. The interviews
used a semi-structured interview guide that asked the par-
ticipants about the appropriateness and usability of the
decision aid in different clinical settings. The decision sci-
entist experts went through a similar process, and were
asked questions relating to the design and structure of the
decision aid with respect to patient decision-making. All
participants in the interview groups were also asked about
the scientific relevance and validity of the content used in
the decision aid and the usability of the decision aid. These
participants were also invited to submit general comments
about the structure and design of the tool.
Each participant across the three groups was asked to
indicate: 1) if they found the decision aid useful and 2) if
they found the decision aid easy to use. Clinicians were




Information gathered from the focus group evaluations
and usability testing provided qualitative feedback about
format and design of the decision aid. Six breast cancer
survivors participated in the patient focus group recruited
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from a patient research registry. Twenty-three participants
completed pilot testing of the decision aid at SABCS, and
five participants completed usability testing of the decision
aid at ISDM. Table 1 presents relevant characteristics of
these participants.
Overall, the participants found the usability of the deci-
sion aid to be favorable. As shown in Table 2, 91% of the
23 clinicians interviewed said they would use the decision
aid in their clinic. Most of the patients and providers who
were interviewed found the decision aid useful and easy to
use. Comments of the participants provided in the focus
group are presented in Table 3. These comments are rep-
resentative of the overall opinion, and form the backbone
of the consensus arrived at during the focus group.
Finalized content (by Modules)
Based on the feedback of the pilot testing (previously re-
ported) [21] and the usability testing reported here, the
following format for the decision aid was decided upon.
A modular design was used in the development of this
tool to allow each patient to focus on the relevant infor-
mation to her situation. The participants indicated that
this kind of design was important to allow patients and
providers to view only the content relevant to them and
to easily skip from one section to another. Providers also
felt that the ability to view sections independently is
intended for use within the clinical visit.
The summary results indicate that the decision aid
was designed in a way that was easy to follow and easy
to use. The predominant opinion of the participants was
that it was important for the tool to remain online to
allow patients to refer to it after the consultation. It was
also important to the participants for the decision aid to
be tailored to each patient’s individual risk of developing
breast cancer.
Based on feedback from the advisory board and scien-
tific advisors, the content was divided into five cohesive
sections presented below. The design of the tool will
allow users to skip modules that are less relevant and
spend more time on modules of greater interest. Figure 1
presents an overview of the decision content.
1) Risk Assessment: Presents a personalized assessment
of a woman’s risk of developing breast cancer. Five-
year and lifetime risk scores are calculated using four
validated models (Gail, Claus, BRCApro, BCSC
Density) [29-32] to provide a more complete initial
screen identifying both family history of breast can-
cer and biological or hormonal exposure risk factors.
The decision aid was designed to that additional
models can added in the future.
2) Perspective & Goals: Compares an individual woman’s
risk of breast cancer to other women and to risk of
other causes of death. Individual breast cancer risks
are compared to an average, age-matched woman to
offer better risk discrimination and to improve risk
communication. Individual breast cancer risks are also
displayed in the context of data on leading causes of
death, such as heart disease and lung cancer, to help
prioritize breast cancer risk.
3) Learning More About Your Risk: Presents
information about tests that can help a woman learn
more about her risk of developing breast cancer.
Biomarkers (such as atypia, breast density and BRCA1
or BRCA2 mutations) stratify patients by risk and
identify the likely benefit from an intervention.
Table 1 Summary of participant characteristics
Patients SABCS participants ISDM participants
Total 6 23 5
Age 44–67 * *
Gender
Female 6 17 3
Male 0 6 2
Characteristics Breast cancer survivors: Specialties: Decision science experts







Caucasian 6 * *
*Not reported.
Ozanne et al. BMC Medical Informatics and Decision Making 2014, 14:4 Page 4 of 8
http://www.biomedcentral.com/1472-6947/14/4
4) Risk Reduction: Provides a comparison of options
for reducing a woman’s risk of developing breast
cancer. Presents information about lifestyle changes,
chemoprevention, and surgical options while
reflecting quality of life trade-offs.
5) Summary & Next Steps: Captures the synopses and
decisions related to risk-assessment and risk-
reduction options for patients and can be incorpo-
rated into medical records.
Discussion
In this paper we have described how BreastHealthDeci-
sions.org has been developed and evaluated as a personal-
ized decision aid that can be used in a primary care setting
to facilitate breast cancer risk reduction discussions. In
developing the tool, we have used an iterative research
process that incorporated feedback from a team of expert
advisors, focus group data and usability interviews with key
stakeholders and potential users of the decision aid. This
process is aligned closely with that developed by Elwyn
and colleagues that has been published since the collection
of these data [35]. The resulting tool is tailored to individ-
ual women and their risk levels and allows for flexible use
during a clinical visit. BreastHealthDecisions.org is a com-
prehensive, personalized decision aid for breast cancer risk
reduction for use in the primary care setting. It fills the
need for an efficient and effective tool that can facilitate
the tasks of risk assessment and risk communication about
breast cancer risk-reduction options.
The efficacy of strategies to reduce the risk of develop-
ing breast cancer has been proven, but these interventions
are not being implemented. In contrast, although the value
of screening mammography is intensely debated, partici-
pation rates for screening are between 72 and 80%. In-
corporating risk stratification and risk-reduction into
routine clinical consultations would provide an opportun-
ity to engage women in the larger context of their overall
breast health, and could identify highest risk women who
would derive the greatest benefit from these interventions.
Studies of women’s decisions about breast cancer pre-
vention and screening conclude that women have a ten-
dency to overestimate both their risk of breast cancer and
the risks of side effects associated with risk-reducing inter-
ventions, leading to suboptimal decision making. The
majority of a cohort of 75 women who had undergone
prophylactic bilateral mastectomy had a significantly exag-
gerated perception of their risk at the time they made their
mastectomy decisions [36]. These women may have
chosen this aggressive intervention due to their inaccurate
understanding of breast cancer risks, highlighting the need
for tools such as BreastHealthDecisions.org to help pro-
viders and patients achieve a more informed view about
the risks an individual faces and the impact of risk redu-
cing options.
Additionally, women often focus on breast cancer risk,
even though they may be at greater risk for other diseases
such as heart disease or lung cancer, risks that can be re-
duced substantially through lifestyle changes. BreastHealth-
Decisions.org was designed to put an individual’s risk of
breast cancer in context with the other health threats she
may face in an effort to combat this bias and help women
make more informed decisions about their health.
Strengths and limitations of development
Although we aimed to design our tool with the greatest
possible generalizability, the web-based nature of
BreastHealthDecisions.org necessitates the use of the
internet and therefore will not be accessible to women or
clinical settings without readily accessible computers. Des-
pite this, it has been designed to be applicable to all
women, regardless of their risk level, which will broaden
its generalizability. The research team is currently working
on corresponding paper-based tools for environments
where use of the internet is limited. Additionally, the deci-
sion aid would be most effective if it were able to develop
a personalized risk of breast cancer in addition to compar-
ing individualized competing health risks. However, there
are currently no risk assessment models that perform this
type of comprehensive risk prediction.




aid easy to use
Clinicians would use decision
aid in their clinic
N (%) N (%) N (%)
Patient group (N = 6) 5 (83) 6 (100) NA
Providers at SABCS (N = 23) 21 (91) 22 (96) 21 (91)
Experts at ISDM (N = 5) 4 (80) 4 (80) NA
Total (N = 34) 30/34 (88) 32/34 (94) 21/23 (91)
Table 3 Focus group consensus comments
Topic Statement representative of group consensus
General reception: “Glad to hear there are prevention tools and methods”
Usability: “The tool is easy to read and follow”
Personalization: “I want to see risks for my situation”
Design: “The color and design are nice”
Format: “I want all the information to be accessible online”
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Variability among providers in communication skills
and knowledge about breast cancer risk reduction may
impact the effectiveness of the tool. For example, a pro-
vider may find it more important to spend time discussing
the risk of heart disease with a patient, even if the patient
herself is more concerned about breast cancer risk. Alter-
natively, the decision tool could prompt the provider to
focus on breast cancer risk reduction even though the pa-
tient is first inclined to discuss other health issues. The
tool is designed to account for this discrepancy in concern
by presenting breast cancer risk information in the context
of other risks, such as heart disease or diabetes.
Strengths and limitations of evaluation
Evaluating BreastHealthDecisions.org through a focus
group enabled us to collect a range of opinions about the
usability and appropriateness of the tool. Using breast can-
cer survivors for our patient focus group meant that they
were able to reflect on their personal experiences and con-
cerns to provide feedback about the content and delivery of
the tool, while their status as survivors made them less
likely to react anxiously to the information. However, it is
possible that survivors may have had a different set of
issues than women at risk of developing breast cancer.
Recruiting at scientific conferences resulted in a diverse set
of clinicians and allowed for multiple testing environments.
In both the pilot study and the focus group, we were
unable to enroll participants from diverse socioeconomic
backgrounds. The large majority of participants were af-
fluent Caucasian women with post-secondary education.
It is a goal for future evaluation to analyze the feasibility
and effectiveness of using BreastHealthDecisions.org
with a more diverse range of women.
Future plans
We are currently implementing the decision aid within
the Athena Breast Health Network, a University of
California-wide consortium. The decision aid will be
used with women identified to be at elevated risk. In
this implementation, we will measure indicators of in-
formed decision-making and resource utilization.
Conclusion
BreastHealthDecisions.org represents a new approach to
integrate breast cancer risk assessment and reduction
into routine care and provides a framework for high
quality preventive healthcare. The ability to integrate
risk assessment and decision support in real time allows
for informed, value-driven, and patient-centered breast
cancer risk reduction decisions. The expected outcome
of our decision aid is improved patient decision-making
regarding breast health: women will be more informed
about their personal risks and the benefits that interven-
tions hold for them, and will make decisions aligned with
their preferences. BreastHealthDecisions.org is designed to
encourage appropriate use of risk-reducing interventions
by identifying women at highest risk, informing patients
and supporting their preferences. Ultimately, improved
decisions and appropriate use of risk-reducing interven-
tions are expected to decrease the incidence and burden
of breast cancer.
Figure 1 Overview of BreastHealthDecisions.org.
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